HRP20150026T1 - 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti - Google Patents
8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti Download PDFInfo
- Publication number
- HRP20150026T1 HRP20150026T1 HRP20150026AT HRP20150026T HRP20150026T1 HR P20150026 T1 HRP20150026 T1 HR P20150026T1 HR P20150026A T HRP20150026A T HR P20150026AT HR P20150026 T HRP20150026 T HR P20150026T HR P20150026 T1 HRP20150026 T1 HR P20150026T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- compound according
- treatment
- crystalline form
- hydroxymethyl
- Prior art date
Links
- HNAXNEBDLULUPW-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;8-chloro-3-pentyl-7h-purine-2,6-dione Chemical compound OCC(N)(CO)CO.O=C1NC(=O)N(CCCCC)C2=C1NC(Cl)=N2 HNAXNEBDLULUPW-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000002329 infrared spectrum Methods 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- CGAMDQCXAAOFSR-UHFFFAOYSA-N 8-chloro-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCCC)C2=C1NC(Cl)=N2 CGAMDQCXAAOFSR-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000012265 solid product Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Spoj, naznačen time što je kristalni 8-klor-3-pentil-3,7-dihidro-1H-purin-2,6-dion tris(hidroksimetil)aminometan anhidrat (Formula (IA):
[image]
2. Spoj prema zahtjevu 1, gdje kristalni oblik spoja je naznačen time što XRPD uzorak sadržava sljedeće pikove:
[image]
3. Spoj prema bilo kojem od zahtjeva 1 do 2, gdje kristalni oblik spoja je naznačen time što ima XRPD uzorak koji izgleda kao što je prikazano na Slici 2.
4. Spoj prema bilo kojem od zahtjeva 1 do 3 gdje kristalni oblik spoja je naznačen time što ima endotermno taljenje s temperaturom početka taljenja od 212 ± 2 °C u DSC termogramu.
5. Spoj prema bilo kojem od zahtjeva 1 do 4 gdje kristalni oblik spoja je naznačen time što ima sljedeće apsorpcijske pikove u ATR-IR spektru krutog produkta: 3370, 3041, 2946, 2858, 1680, 1656, 1528, 1266, 1243, 1078, 1068, 1049 ± 1 cm-1.
6. Spoj prema bilo kojem od zahtjeva 1 do 5 gdje kristalni oblik spoja je naznačen time što ima ATR infracrveni spektar koji izgleda kao što je prikazano na Slici 6.
7. Kombinacija, naznačena time što sadržava a) spoj kao što je definirano u bilo kojem od prethodnih zahtjeva 1 do 6 i b) jedno ili više terapijski aktivnih sredstava.
8. Spoj kao što je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time što se koristi u terapiji.
9. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje miješane dislipidemije, dijabetičke dislipidemije ili hiperlipoproteinemije.
10. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje diabetes mellitus-a tipa II.
11. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje dijabetičke dislipidemije, miješane dislipidemije, otkazivanja srca, hiperkolesterolemije, kardiovaskularne bolesti, ateroskleroze, arterioskleroze, hipertrigliceridemije, diabetes mellitus-a tipa II, dijabetesa tipa II, otpornosti na inzulin, hiperlipidemije, anoreksije nervose, pretilosti, bolesti koronarnih arterija, tromboze, angine, kroničnog otkazivanja bubrega, periferne vaskularne bolesti ili kapi.
12. Spoj prema zahtjevu 8, naznačen time što se upotrebljava za liječenje multiple skleroze.
13. Farmaceutski pripravak, naznačen time što sadržava: a) spoj kao što je definirano u bilo kojem od zahtjeva 1 do 6 i b) jedan ili više farmaceutski prihvatljivih nosača.
14. Postupak za dobivanje spoja kao što je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time što spomenuti postupak sadržava korak miješanja spoja Formule (A)
[image]
s tris(hidroksimetil)aminometanom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12059608P | 2008-12-08 | 2008-12-08 | |
| PCT/US2009/066941 WO2010068581A1 (en) | 2008-12-08 | 2009-12-07 | Novel compounds |
| EP09832421.3A EP2370440B1 (en) | 2008-12-08 | 2009-12-07 | 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150026T1 true HRP20150026T1 (hr) | 2015-02-13 |
Family
ID=42243044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150026AT HRP20150026T1 (hr) | 2008-12-08 | 2015-01-09 | 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9163024B2 (hr) |
| EP (1) | EP2370440B1 (hr) |
| JP (1) | JP5666464B2 (hr) |
| KR (1) | KR101743783B1 (hr) |
| CN (1) | CN102245606B (hr) |
| AU (1) | AU2009324811B2 (hr) |
| BR (1) | BRPI0922134A2 (hr) |
| CA (1) | CA2746316C (hr) |
| CY (1) | CY1116032T1 (hr) |
| DK (1) | DK2370440T3 (hr) |
| EA (1) | EA020037B1 (hr) |
| ES (1) | ES2527354T3 (hr) |
| HR (1) | HRP20150026T1 (hr) |
| IL (1) | IL213032A (hr) |
| MX (1) | MX2011006022A (hr) |
| PL (1) | PL2370440T3 (hr) |
| PT (1) | PT2370440E (hr) |
| RS (1) | RS53777B1 (hr) |
| SI (1) | SI2370440T1 (hr) |
| SM (1) | SMT201500012B (hr) |
| WO (1) | WO2010068581A1 (hr) |
| ZA (1) | ZA201103397B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1781657T3 (pl) * | 2004-02-14 | 2013-08-30 | Glaxosmithkline Ip Dev Ltd | Leki o aktywności wobec receptora HM74A |
| EP2272848B1 (en) | 2005-08-10 | 2012-12-26 | Glaxosmithkline LLC | Xanthine derivatives as selective HM74A agonists |
| NZ629203A (en) * | 2012-03-22 | 2015-12-24 | Vtv Therapeutics Llc | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657327A (en) * | 1970-06-01 | 1972-04-18 | Upjohn Co | Prostaglandin salts of tris(hydroxymethyl)aminomethane |
| US4647585A (en) | 1984-11-08 | 1987-03-03 | E. R. Squibb & Sons, Inc. | Bicycloheptane substituted ethers |
| EP1237851A4 (en) * | 1999-12-15 | 2004-06-23 | Smithkline Beecham | SALES OF I CIS / I-4-CYANO-4-3- (CYCLOPENTYLOXY) -4-METHOXYPHENYL] CYCLHEXAN-1-CARBONIC ACID |
| US20030013905A1 (en) | 2002-06-10 | 2003-01-16 | Huang Guishu Kris | Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid |
| PL1781657T3 (pl) * | 2004-02-14 | 2013-08-30 | Glaxosmithkline Ip Dev Ltd | Leki o aktywności wobec receptora HM74A |
| GB0423568D0 (en) * | 2004-10-22 | 2004-11-24 | Smithkline Beecham Corp | Novel compounds |
| US20090209561A1 (en) | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| GB0516464D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| EP2272848B1 (en) | 2005-08-10 | 2012-12-26 | Glaxosmithkline LLC | Xanthine derivatives as selective HM74A agonists |
-
2009
- 2009-12-07 KR KR1020117012975A patent/KR101743783B1/ko not_active Application Discontinuation
- 2009-12-07 BR BRPI0922134-4A patent/BRPI0922134A2/pt not_active Application Discontinuation
- 2009-12-07 CN CN200980148973.7A patent/CN102245606B/zh not_active Expired - Fee Related
- 2009-12-07 US US13/133,486 patent/US9163024B2/en not_active Expired - Fee Related
- 2009-12-07 JP JP2011539772A patent/JP5666464B2/ja not_active Expired - Fee Related
- 2009-12-07 WO PCT/US2009/066941 patent/WO2010068581A1/en active Application Filing
- 2009-12-07 CA CA2746316A patent/CA2746316C/en not_active Expired - Fee Related
- 2009-12-07 EP EP09832421.3A patent/EP2370440B1/en active Active
- 2009-12-07 SI SI200931113T patent/SI2370440T1/sl unknown
- 2009-12-07 DK DK09832421.3T patent/DK2370440T3/en active
- 2009-12-07 PL PL09832421T patent/PL2370440T3/pl unknown
- 2009-12-07 ES ES09832421.3T patent/ES2527354T3/es active Active
- 2009-12-07 AU AU2009324811A patent/AU2009324811B2/en not_active Ceased
- 2009-12-07 RS RS20150086A patent/RS53777B1/en unknown
- 2009-12-07 EA EA201170783A patent/EA020037B1/ru not_active IP Right Cessation
- 2009-12-07 PT PT98324213T patent/PT2370440E/pt unknown
- 2009-12-07 MX MX2011006022A patent/MX2011006022A/es active IP Right Grant
-
2011
- 2011-05-10 ZA ZA2011/03397A patent/ZA201103397B/en unknown
- 2011-05-19 IL IL213032A patent/IL213032A/en not_active IP Right Cessation
-
2014
- 2014-12-16 CY CY20141101047T patent/CY1116032T1/el unknown
-
2015
- 2015-01-09 HR HRP20150026AT patent/HRP20150026T1/hr unknown
- 2015-01-16 SM SM201500012T patent/SMT201500012B/xx unknown
- 2015-08-31 US US14/840,549 patent/US20150366870A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/289,996 patent/US20170027945A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012511028A (ja) | 2012-05-17 |
| CN102245606B (zh) | 2014-08-20 |
| EA201170783A1 (ru) | 2011-12-30 |
| CN102245606A (zh) | 2011-11-16 |
| KR20110097816A (ko) | 2011-08-31 |
| AU2009324811B2 (en) | 2013-01-24 |
| EP2370440B1 (en) | 2014-11-12 |
| IL213032A0 (en) | 2011-07-31 |
| US20110251218A1 (en) | 2011-10-13 |
| EP2370440A1 (en) | 2011-10-05 |
| PT2370440E (pt) | 2015-01-14 |
| SMT201500012B (it) | 2015-05-03 |
| ZA201103397B (en) | 2012-01-25 |
| SI2370440T1 (sl) | 2015-02-27 |
| CA2746316A1 (en) | 2010-06-17 |
| MX2011006022A (es) | 2011-06-28 |
| AU2009324811A1 (en) | 2011-06-23 |
| DK2370440T3 (en) | 2014-12-08 |
| KR101743783B1 (ko) | 2017-06-05 |
| US9163024B2 (en) | 2015-10-20 |
| WO2010068581A1 (en) | 2010-06-17 |
| CY1116032T1 (el) | 2017-01-25 |
| JP5666464B2 (ja) | 2015-02-12 |
| US20170027945A1 (en) | 2017-02-02 |
| BRPI0922134A2 (pt) | 2015-08-18 |
| EA020037B1 (ru) | 2014-08-29 |
| US20150366870A1 (en) | 2015-12-24 |
| RS53777B1 (en) | 2015-06-30 |
| CA2746316C (en) | 2017-01-03 |
| ES2527354T3 (es) | 2015-01-22 |
| EP2370440A4 (en) | 2012-05-30 |
| PL2370440T3 (pl) | 2015-05-29 |
| IL213032A (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920002131B1 (ko) | 타아졸리딘디온 유도체의 제조방법 | |
| HRP20150026T1 (hr) | 8-klor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiol anhidrat za lijeäśenje bolesti | |
| CZ30899A3 (cs) | Substituovaný pyridin a bifenyl jako antihypercholesterinemické, antihyperlipoproteinemické a antihyperglykemické přípravky | |
| JP2021521265A (ja) | Ｇｌｐ−１受容体アゴニストおよびその使用 | |
| KR20190094433A (ko) | Glp-1 수용체 작용제 및 이의 용도 | |
| JP2005170790A (ja) | Ｎ−アルキルスルフォニル置換アミド誘導体 | |
| JP2011515341A (ja) | 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体 | |
| JP2011515341A5 (hr) | ||
| NO343371B1 (no) | Nye forbindelser med DGAT1-aktivitet, farmasøytiske sammensetninger inneholdende slike og anvendelse derav | |
| JP2008500354A (ja) | Ｐｐａｒモジュレーターとしての化合物および組成物 | |
| JP2016512534A5 (hr) | ||
| JP2007537289A (ja) | Ｐｐａｒモジュレーターとしての化合物および組成物 | |
| WO2005115384A3 (en) | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation | |
| RU2642454C2 (ru) | Производные мочевины и их применение в качестве ингибиторов белка, связывающего жирные кислоты | |
| WO2008000408A1 (en) | Cxcr2 antagonists | |
| CN101386604A (zh) | 抑制黄嘌呤氧化酶活性的芳腈基噻唑衍生物及制备方法和用途 | |
| JP2010534210A (ja) | アリールピリミジン誘導体、その製造方法、及び、その使用 | |
| WO2011151436A2 (en) | Novel compounds, method for use them and pharmaceutical composition containing them | |
| CN102219638A (zh) | 一种烯基羧酸的氟化方法 | |
| CA2626443A1 (en) | Oxazole and thiazole ppar modulators | |
| CN101146812A (zh) | 光学活性铵盐化合物、其制造中间体和制造方法 | |
| JP2012511028A5 (hr) | ||
| JP2023540337A (ja) | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤として有用な新規ビアリール誘導体及びその使用 | |
| TWI821237B (zh) | 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物 | |
| CN101821226A (zh) | 白三烯b4抑制剂 |